TY - JOUR
T1 - Isolation protocol of mouse monocyte-derived dendritic cells and their subsequent in vitro activation with tumor immune complexes
AU - Santana-Magal, Nadine
AU - Rasoulouniriana, Diana
AU - Saperia, Corey
AU - Gutwillig, Amit
AU - Rider, Peleg
AU - Engleman, Edgar G.
AU - Carmi, Yaron
N1 - Publisher Copyright:
© 2018 Journal of Visualized Experiments.
PY - 2018/5/31
Y1 - 2018/5/31
N2 - Dendritic cells (DC) are heterogeneous cell populations that differ in their cell membrane markers, migration patterns and distribution, and in their antigen presentation and T cell activation capacities. Since most vaccinations of experimental tumor models require millions of DC, they are widely isolated from the bone marrow or spleen. However, these DC significantly differ from blood and tumor DC in their responses to immune complexes (IC), and presumably to other Syk-coupled lectin receptors. Importantly, given the sensitivity of DC to danger-associated molecules, the presence of endotoxins or antibodies that crosslink activation receptors in one of the isolating steps could result in the priming of DC and thus affect the parameters, or at least the dosage, required to activate them. Therefore, here we describe a detailed protocol for isolating MoDC from blood and tumors while avoiding their premature activation. In addition, a protocol is provided for MoDC activation with tumor IC, and their subsequent analyses.
AB - Dendritic cells (DC) are heterogeneous cell populations that differ in their cell membrane markers, migration patterns and distribution, and in their antigen presentation and T cell activation capacities. Since most vaccinations of experimental tumor models require millions of DC, they are widely isolated from the bone marrow or spleen. However, these DC significantly differ from blood and tumor DC in their responses to immune complexes (IC), and presumably to other Syk-coupled lectin receptors. Importantly, given the sensitivity of DC to danger-associated molecules, the presence of endotoxins or antibodies that crosslink activation receptors in one of the isolating steps could result in the priming of DC and thus affect the parameters, or at least the dosage, required to activate them. Therefore, here we describe a detailed protocol for isolating MoDC from blood and tumors while avoiding their premature activation. In addition, a protocol is provided for MoDC activation with tumor IC, and their subsequent analyses.
KW - Cancer research
KW - Dendritic cells
KW - Fcγ receptors
KW - Immune complexes
KW - Issue 135
KW - MAP kinases
KW - Monocyte-derived DC
KW - Tumor-associated DC
KW - Tyrosine phosphatase
UR - http://www.scopus.com/inward/record.url?scp=85052168988&partnerID=8YFLogxK
U2 - 10.3791/57188
DO - 10.3791/57188
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:85052168988
SN - 1940-087X
VL - 2018
JO - Journal of Visualized Experiments
JF - Journal of Visualized Experiments
IS - 135
M1 - e57188
ER -